^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Dendritic cell renal cell carcinoma fusion vaccine

    i
    Associations
    News

    Trials

    Company:
    Beth Israel Deaconess Medical Center
    Drug class:
    Immunostimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF (NCT00458536)
    Phase 1/2
    Beth Israel Deaconess Medical Center
    Completed
    Last update posted :
    04/03/2024
    Initiation :
    10/01/2004
    Primary completion :
    12/01/2014
    Completion :
    07/01/2023
    CSF2
    |
    Dendritic cell renal cell carcinoma fusion vaccine